RxDoctor Payments Data

Omar Tamimi, MD

Gastroenterology · Toms River, NJNPI 1932148327

Payments from drug & device makers

$510in general payments, 2019–2025

Across 15 payments — averaging $33.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$102
  • AbbVie$97
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$95
  • Medtronic$88
  • Cook Medical LLC$52
  • Ferring Pharmaceuticals Inc.$29
  • plus $47 from 3 others

What the payments were for

  • Speaking & faculty fees$204%
  • Grants$204%
  • Food & beverage$47092%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$510 in reported general payments places this provider in the 20th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$259,577
Medicare patients
1,011
Services billed
1,960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase114$487,571
LinzessLinaclotide76$80,061
Humira(Cf) PenAdalimumab12$78,752
XeljanzTofacitinib Citrate14$78,472
ZenpepLipase/Protease/Amylase25$78,432
PentasaMesalamine24$72,690
Dexlansoprazole DrDexlansoprazole198$72,485
RinvoqUpadacitinib12$71,643
XifaxanRifaximin21$61,990
Mesalamine74$56,855
Alosetron Hcl12$24,970
DexilantDexlansoprazole17$16,397
Famotidine873$15,679
TrulancePlecanatide19$15,648
Pantoprazole Sodium1,021$14,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Rinvoq$97$639,275202 claims
PfizerXeljanz$11$78,47214 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$95$77,63940 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$18$16,39717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →